GlaxoSmithKline (GSK) announced that 60% of patients with relapsed / refractory multiple myeloma securing GSK2857916 anti-B-cell maturation antigen (BCMA) antibody-drug conjugate achieved an overall response rate (ORR) in DREAMM-1 study. The further positive data from […]
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing. The Company plans to use the proceeds from […]
North American pharma company CytoDyn has announced that its primary product leronlimab exceeded expectations as a monotherapy for human immunodeficiency virus (HIV). The company has published new data that shows a weekly 525mg and 700mg […]
SMi Group Reports: SMi Group would like to remind all microbiologists that 2nd Annual Pharmaceutical Microbiology East Coast Conference and Exhibition will be taking place in Boston, USA, on April 10 and 11, 2019, in […]
Conatus Pharmaceuticals has announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement […]